| URL | https://www.fiercepharma.com/pharma/part-amgen-s-t |
| Source | FiercePharma |
| Date Published | 02/06/2018 |
| Author Name | Eric Palmer |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Amgen |
| Parent company | Amgen Inc |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 300 |
| Capital investment ($): | 300 |
| Country(ies) from which reshored: | Singapore |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | biotech |
| What domestic positive factors made reshoring more attractive? | Customer responsiveness improvement, Government Incentives, Higher productivity |